|
|
|
38 Utah Companies have raised over $201 million from the Utah Fund of Funds portfolios funds. -------------------------------------------------------- Visited with 25 funds. -------------------------------------------------------- Established 47 introductions. -------------------------------------------------------- The jobs created will produce over $100 million in tax revenue over the next 10 years. -------------------------------------------------------- The Utah Fund of Funds portfolio has an aggregate of $5 billion investable capital. -------------------------------------------------------- Over 350 Utah companies have been reviewed by Utah Fund of Fund portfolio managers. -------------------------------------------------------- More Statistics> |
 Utah Fund of Funds Investments
Upstart Life Sciences Capital invests in start up and early stage healthcare companies. Most of the startups are based on breakthrough technologies from major research universities in Utah and nearby states. The Fund focuses on medical devices, drug delivery systems, diagnostics, and biopharma. Key Contacts - STEVEN BORST (Principal): Mr. Borst currently serves as Vice President of Finance and Corporate Development at Q Therapeutics. He has a background managing venture capital firms and healthcare related companies, most recently as a General Partner of Utah Ventures, an early stage healthcare and information technology fund in Salt Lake City. Previously, he was a founder and served as Vice President of Business Development at American WholeHealth, Inc., a venture-backed health care services company in Reston, Virginia. There, Mr. Borst led the acquisition of physician practices and practitioner networks. Before that, he was a healthcare associate at Frontenac Company, a Chicago venture capital firm focused on healthcare, information technology and consumer-based opportunities. Prior thereto, Mr. Borst served as Vice President of Operations and then Chief Executive Officer of Applied Computer Technology for Patient Care, Inc., a Madison, Wisconsin, venture-backed developer and marketer of medically oriented information systems. Earlier, he was an associate at Capital Health Venture Partners, a Chicago venture fund focused on medical and biotechnology investments. Mr. Borst received a B.S. in Industrial Engineering from the University of Michigan and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University. - DENNIS FARRAR (Principal): Mr. Farrar co-founded and was most recently Chief Executive Officer of Q Therapeutics, until he resigned in September 2006 to devote full time to Upstart Fund activities. Over the last 15 years, he has co-founded seven Salt Lake City-based life sciences companies, four of which (including Myriad Genetics) are now public companies. Mr. Farrar was the initial CEO at four of the companies. The public companies include Myriad Genetics, a gene therapeutics and diagnostics company; Sonic Innovations, a digital hearing aid company; Acacia Biosciences, a gene profiling company that was merged into Rosetta Inpharmatics which in turn was acquired by Merck for $620 million; and Arcaris, a drug target validation company acquired by Deltagen. Mr. Farrar is an attorney who has specialized in corporate law, including the representation of health care related companies. He was a partner at Van Cott, Bagley, Cornwall & McCarthy in Salt Lake City, and was previously associated with Debevoise & Plimpton in New York City and McCutchen, Doyle, Brown & Enersen in San Francisco. Mr. Farrar received his law degree from Stanford Law School, where he was an editor of the Law Review, and received a B.A. degree in political science from Stanford University. - THEODORE STANLEY (Principal): Dr. Stanley is currently the Chairman of ZARS, Inc., a private trans-dermal drug delivery company in Salt Lake City, which he co-founded in 1996. To date, ZARS has raised a total of $42 million in venture funding, has two products approved for market and two others in late stage clinical trials. Dr. Stanley is a Professor of Anesthesiology and Surgical Research at the University of Utah, where he has been employed for almost 40 years. During that period, he and his associates received over $10 million in government and pharmaceutical company funding. In 1985, Dr. Stanley was a co-founder and Chairman of Anesta Corporation, a Salt Lake trans-mucosal drug delivery company which was acquired by Cephalon in 2000 for $455 million. Its most successful product, Actiq, developed by Anesta, generated sales of $625 million in 2006. Dr. Stanley also co-founded a Salt Lake-based healthcare services company. Dr. Stanley graduated from Columbia College and received his M.D. from Columbia University. He has been the Director of the Anesthesiology Research Laboratory at the University of Utah for over 20 years and is internationally recognized for his development work on opioids, other intravenous anesthetics, and novel drug delivery techniques. << Back to Portfolio list |
|||||||||||||||||
| Privacy | Legal Disclaimer | ||||||||||||||||||
|